NasdaqGS - Delayed Quote • USD
Regeneron Pharmaceuticals, Inc. (REGN)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 20 | 20 | 26 | 25 |
| Avg. Estimate | 10.12 | 11.01 | 45.22 | 47.53 |
| Low Estimate | 8.56 | 9.27 | 36.48 | 41.73 |
| High Estimate | 12.34 | 12.75 | 52.6 | 56.4 |
| Year Ago EPS | 10.09 | 10.24 | 43.79 | 45.22 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 17 | 26 | 25 |
| Avg. Estimate | 3.22B | 3.39B | 13.95B | 14.96B |
| Low Estimate | 3B | 3.15B | 13.04B | 13.69B |
| High Estimate | 3.51B | 3.65B | 14.75B | 17.18B |
| Year Ago Sales | 3B | -- | 13.12B | 13.95B |
| Sales Growth (year/est) | 7.20% | -- | 6.30% | 7.20% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 9.56 | 9.84 | 10.72 | 10.73 |
| EPS Actual | 10.09 | 10.24 | 11.59 | 11.86 |
| Difference | 0.53 | 0.4 | 0.87 | 1.13 |
| Surprise % | 5.50% | 4.10% | 8.10% | 10.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 10.12 | 11.01 | 45.22 | 47.53 |
| 7 Days Ago | 9.96 | 10.95 | 44.87 | 47.39 |
| 30 Days Ago | 9.96 | 10.95 | 44.74 | 47.23 |
| 60 Days Ago | 10.02 | 11.06 | 44.91 | 47.14 |
| 90 Days Ago | 10.41 | 11.22 | 44.44 | 47.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 3 | 2 |
| Up Last 30 Days | 5 | 5 | 7 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 2 | 2 |
Growth Estimates
| CURRENCY IN USD | REGN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 0.30% | -- | -- | 0.80% |
| Next Qtr. | 7.50% | -- | -- | 9.60% |
| Current Year | 3.30% | -- | -- | 4.50% |
| Next Year | 5.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 7.36% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 17.45% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/17/2024 |
| Maintains | UBS: Buy to Buy | 4/17/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 4/15/2024 |
| Maintains | B of A Securities: Underperform to Underperform | 4/12/2024 |
| Reiterates | RBC Capital: Outperform to Outperform | 4/9/2024 |
| Maintains | Truist Securities: Buy to Buy | 4/3/2024 |
Related Tickers
VRTX Vertex Pharmaceuticals Incorporated
393.48
+0.10%
BMRN BioMarin Pharmaceutical Inc.
90.07
-0.44%
VERA Vera Therapeutics, Inc.
39.48
-1.32%
BHVN Biohaven Ltd.
42.16
-4.25%
MDGL Madrigal Pharmaceuticals, Inc.
222.26
-2.66%
CRSP CRISPR Therapeutics AG
56.16
+1.08%
NTLA Intellia Therapeutics, Inc.
21.32
-0.84%
VKTX Viking Therapeutics, Inc.
64.67
-2.71%
BNTX BioNTech SE
86.17
-0.27%
ALPN Alpine Immune Sciences, Inc.
64.43
-0.05%